These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 7597305)

  • 41. Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma.
    Atkins MB; O'Boyle KR; Sosman JA; Weiss GR; Margolin KA; Ernest ML; Kappler K; Mier JW; Sparano JA; Fisher RI
    J Clin Oncol; 1994 Aug; 12(8):1553-60. PubMed ID: 8040667
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma.
    Atkins MB; Gollob JA; Sosman JA; McDermott DF; Tutin L; Sorokin P; Parker RA; Mier JW
    Clin Cancer Res; 2002 Oct; 8(10):3075-81. PubMed ID: 12374674
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma.
    Sasse AD; Sasse EC; Clark LG; Ulloa L; Clark OA
    Cochrane Database Syst Rev; 2007 Jan; (1):CD005413. PubMed ID: 17253556
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Interferon-alpha and interleukin-2 in the treatment of metastatic melanoma. Comparison of two phase II trials.
    Keilholz U; Scheibenbogen C; Tilgen W; Bergmann L; Weidmann E; Seither E; Richter M; Brado B; Mitrou PS; Hunstein W
    Cancer; 1993 Jul; 72(2):607-14. PubMed ID: 8319195
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The role of interleukin-2 in the management of stage IV melanoma: the EORTC melanoma cooperative group program.
    Keilholz U; Eggermont AM
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S99-103. PubMed ID: 10685668
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rationale for intergroup trial E-3695 comparing concurrent biochemotherapy with cisplatin, vinblastine, and DTIC alone in patients with metastatic melanoma.
    Flaherty LE
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S15-20. PubMed ID: 10685653
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma.
    McDermott DF; Mier JW; Lawrence DP; van den Brink MR; Clancy MA; Rubin KM; Atkins MB
    Clin Cancer Res; 2000 Jun; 6(6):2201-8. PubMed ID: 10873069
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sequential dacarbazine/cisplatin and interleukin-2 in metastatic melanoma: immunological effects of therapy.
    Redman BG; Flaherty L; Chou TH; Nakeff A; Pillote K; Kaplan J
    J Immunother (1991); 1991 Apr; 10(2):147-51. PubMed ID: 2043595
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Treatment of metastasized malignant melanoma].
    Kamanabrou D
    Praxis (Bern 1994); 2001 Mar; 90(10):391-6. PubMed ID: 11305184
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Chemoimmunotherapy with dacarbazine and aranose combined with interferon-alpha in disseminated cutaneous melanoma].
    Gershanovich ML; Akimov MA
    Vopr Onkol; 2004; 50(2):179-83. PubMed ID: 15176220
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Nitric oxide and neopterin levels and clinical response in stage III melanoma patients receiving concurrent biochemotherapy.
    Anderson CM; Buzaid AC; Sussman J; Lee JJ; Ali-Osman F; Braunschweiger PG; Plager C; Bedikian A; Papadopoulos N; Eton O; Legha SS; Grimm EA
    Melanoma Res; 1998 Apr; 8(2):149-55. PubMed ID: 9610868
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Recombinant interleukin-2-based treatments for advanced melanoma: the experience of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group.
    Keilholz U; Stoter G; Punt CJ; Scheibenbogen C; Lejeune F; Eggermont AM
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S22-8. PubMed ID: 9457389
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A phase II study of dacarbazine, cisplatin, interferon-alpha and high-dose interleukin-2 in 'poor-risk' metastatic melanoma.
    Proebstle TM; Scheibenbogen C; Sterry W; Keilholz U
    Eur J Cancer; 1996 Aug; 32A(9):1530-3. PubMed ID: 8911113
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Risk and outcome in metastatic malignant melanoma patients receiving DTIC, cisplatin, BCNU and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha2a.
    Hoffmann R; Müller I; Neuber K; Lassmann S; Buer J; Probst M; Oevermann K; Franzke A; Kirchner H; Ganser A; Atzpodien J
    Br J Cancer; 1998 Oct; 78(8):1076-80. PubMed ID: 9792153
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term survival in metastatic melanoma patients treated with sequential biochemotherapy: report of a Phase II study.
    Neri B; Vannozzi L; Fulignati C; Pantaleo P; Pantalone D; Paoletti C; Perfetto F; Turrini M; Mazzanti R
    Cancer Invest; 2006; 24(5):474-8. PubMed ID: 16939954
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Does complete response to systemic therapy in patients with stage IV melanoma translate into long-term survival?
    Bedikian AY; Johnson MM; Warneke CL; Papadopoulos NE; Kim KB; Hwu WJ; McIntyre S; Rohlfs M; Homsi J; Hwu P
    Melanoma Res; 2011 Feb; 21(1):84-90. PubMed ID: 21102360
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Chemoimmunotherapy of metastatic malignant melanoma. The Salpétrière Hospital (SOMPS) experience.
    Khayat D; Antoine E; Rixe O; Tourani JM; Vuillemin E; Borel C; Benhammouda A; Thill L; Franks C; Auclerc G
    Eur J Cancer; 1993; 29A Suppl 5():S2-5. PubMed ID: 8260262
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Role of interferons in the therapy of melanoma.
    Castello G; Ruocco V; Satriano RA; Zarrilli D
    Melanoma Res; 1992; 1(5-6):311-25. PubMed ID: 1384854
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A phase II study of biochemotherapy for the treatment of metastatic malignant melanoma.
    Gibbs P; Iannucci A; Becker M; Allen J; O'Driscoll M; McDowell K; Williams P; Rosse P; Murphy J; Gonzalez R
    Melanoma Res; 2000 Apr; 10(2):171-9. PubMed ID: 10803718
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD) plus interferon alpha for metastatic melanoma: a multicentre phase II study.
    Punt CJ; van Herpen CM; Jansen RL; Vreugdenhil G; Muller EW; de Mulder PH
    Br J Cancer; 1997; 76(2):266-9. PubMed ID: 9231931
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.